0000950172-24-000190.txt : 20240415
0000950172-24-000190.hdr.sgml : 20240415
20240415173025
ACCESSION NUMBER: 0000950172-24-000190
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240412
FILED AS OF DATE: 20240415
DATE AS OF CHANGE: 20240415
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hooks Corwin Dale
CENTRAL INDEX KEY: 0001665347
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38898
FILM NUMBER: 24845620
MAIL ADDRESS:
STREET 1: C/O CLOVIS ONCOLOGY, INC.
STREET 2: 5500 FLATIRON PARKWAY
CITY: BOULDER
STATE: CO
ZIP: 80301
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Applied Therapeutics, Inc.
CENTRAL INDEX KEY: 0001697532
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 545 FIFTH AVENUE, SUITE 1400
CITY: NEW YORK
STATE: NY
ZIP: 10017
BUSINESS PHONE: 212-220-9226
MAIL ADDRESS:
STREET 1: 545 FIFTH AVENUE, SUITE 1400
CITY: NEW YORK
STATE: NY
ZIP: 10017
FORMER COMPANY:
FORMER CONFORMED NAME: Applied Therapeutics Inc.
DATE OF NAME CHANGE: 20170208
4
1
form4.xml
X0508
4
2024-04-12
0001697532
Applied Therapeutics, Inc.
APLT
0001665347
Hooks Corwin Dale
C/O APPLIED THERAPEUTICS, INC.
545 FIFTH AVENUE, SUITE 1400
NEW YORK
NY
10017
true
Chief Commercial Officer
false
Common Stock
2024-04-12
4
A
0
300000
0
A
300000
D
Consists of compensatory Restricted Stock Units granted under Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan. Each compensatory Restricted Stock Unit represents a contingent right to receive one share of the issuer's common stock. One fourth (1/4th) of the compensatory Restricted Stock Units shall vest on April 12, 2025, and one thirty-sixth (1/36th) of the remaining shares subject to the compensatory Restricted Stock Units shall vest each month thereafter, subject to the reporting person continuing to provide services through each such date.
/s/ Shoshana Shendelman, as attorney-in-fact
2024-04-15